文献速递糖尿病

达格列净按基线胰岛素方案和剂量给药的疗效与安全性:DECLARE-TIMI 58 事后分析

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
PubMed 文献 · Diabetes Care · 2023-01-01

DECLARE-TIMI 58 试验事后分析纳入 17,160 例 2 型糖尿病患者,随机接受达格列净或安慰剂,中位随访 4.2 年。在 7,013 例基线胰岛素使用者中,达格列净降低心血管死亡/心力衰竭住院(HR 0.82,95%CI 0.69-0.97),且不受胰岛素方案或剂量影响,安全性与已知特征一致。

要点

  • 胰岛素使用者中,达格列净降低心血管死亡/心衰住院(HR 0.82,95%CI 0.69-0.97)。
  • 含或不含短效胰岛素的方案间,心血管获益一致(交互作用 P=0.75)。
  • 不同胰岛素剂量亚组间,主要不良心血管事件获益相似(交互作用 P=0.07)。

核心结论

  • 在接受高剂量或强化胰岛素方案(包括短效胰岛素)的高危患者中,达格列净的获益和安全性得以维持。

研究设计与样本

  • DECLARE-TIMI 58 试验事后分析,17,160 例 2 型糖尿病患者随机接受达格列净或安慰剂,中位随访 4.2 年。
  • 基线胰岛素使用者共 7,013 例,其中 4,650 例(66.3%)使用含短效胰岛素的方案。
  • 胰岛素剂量分布:<0.5 IU/kg 者 2,443 例(34.8%),0.5 至 ≤1 IU/kg 者 2,795 例(39.9%),>1 IU/kg 者 1,339 例(19.1%)。

主要发现

  • 总体胰岛素使用者中,达格列净降低心血管死亡/心力衰竭住院(HR 0.82,95%CI 0.69-0.97)。
  • 含短效胰岛素方案者 HR 0.83(95%CI 0.67-1.03),不含短效胰岛素方案者 HR 0.78(95%CI 0.57-1.07),交互作用 P=0.75。
  • 按胰岛素剂量分层,心血管死亡/心衰住院无 heterogeneity(交互作用 P=0.43)。
  • 胰岛素使用者中,达格列净降低主要不良心血管事件(HR 0.84,95%CI 0.74-0.97),方案和剂量交互作用 P 分别为 0.75 和 0.07。
  • 达格列净降低肾脏不良结局发生率,且在胰岛素使用者各亚组中一致;HbA1c、体重和收缩压的下降与胰岛素剂量或方案无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The cardiorenal benefits of adding sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy for patients on insulin, particularly those on intensive regimens that include short-acting (SA) insulin, have not been explored. RESEARCH DESIGN AND METHODS: In Dapagliflozin Effect on Cardiovascular Events trial (DECLARE-TIMI 58), 17,160 patients with type 2 diabetes were randomized to dapagliflozin or placebo for a median follow-up of 4.2 years. Cardiovascular (CV), renal, metabolic, and safety outcomes with dapagliflozin versus placebo by insulin dose and regimen were studied with Cox regression models. RESULTS: The study included 7,013 insulin users at baseline, with 4,650 (66.3%) patients on regimens including SA insulin. Insulin doses varied, with 2,443 (34.8%) patients receiving <0.5 IU/kg, 2,795 (39.9%) 0.5 to ≤1 IU/kg, and 1,339 (19.1%) >1 IU/kg. Dapagliflozin reduced CV death/hospitalization for heart failure among overall insulin users (hazard ratio [HR] 0.82 [95% CI 0.69-0.97]) and consistently in patients on insulin regimens with or without SA insulin (0.83 [0.67-1.03] and 0.78 [0.57-1.07], respectively, Pinteraction = 0.75). No heterogeneity was observed by insulin dose (Pinteraction = 0.43). The HR for major adverse CV events with dapagliflozin among insulin users (0.84 [0.74-0.97]) was similar irrespective of regimen or dose (Pinteraction = 0.75 and 0.07). Dapagliflozin reduced the rate of adverse renal outcomes overall and consistently across subgroups of insulin users. Decreases in HbA1c, weight, and systolic blood pressure with dapagliflozin were seen regardless of insulin dose or regimen. The known safety profile of dapagliflozin was unchanged in patients on intensive insulin regimens. CONCLUSIONS: The benefits and safety of dapagliflozin were maintained in high-risk patients receiving high-dose or intensive insulin regimens including SA insulin.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Pollack R, Raz I, Wiviott SD, et al. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. Diabetes Care. 2023. PMID: 36399721. doi:10.2337/dc22-1318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。